Nintedanib esylate

Product Category
Product Code
CAS Number
MDL Number
Pubchem CID
Reaxys RN
Nintedanib Ethanesulfonate Salt, BIBF1120 esylate
API & Intermediates
Chemical Name
Molecular Formula
Molecular Weight
Melting Point
Nintedanib esylate
Bright Yellow Solid
500mg,1g,10g,25g,50g,100g and 500g
-20°C Freezer
Nintedanib esylate (also known as Nintedanib Ethanesulfonate Salt, BIBF1120 esylate) is the ethanesulfonate salt form of BIBF1120 (Nintedanib), which is a small molecule tyrosine-kinase inhibitor, targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet derived growth factor receptor (PDGFR).
BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. [1]
An Open-label Dose-escalation Study of BIBF 1120 in Patients with Relapsed or Refractory Multiple Myeloma. [2]
A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). [3]
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies. [4]
Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. [5]
Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor, and pemetrexed in pretreated non-small cell lung cancer patients. [6]
Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis. [7]
New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. [8]
Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. [9]
Nintedanib in the treatment of idiopathic pulmonary fibrosis. [10]
Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties. [11]
Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials. [12]
Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis. [13]
[1] F.Hillberg, et al, Cancer Res., 2008, 68(12), pp 4774-4782.
[2] M.Kropff, et al, Anticancer Res., 2009, 29(10), pp 4233-4238.
[3] J.A.Ledermann, et al, J. Clin. Oncol., 2009, 27(15s), pp 5501-5501.
[4] A.du Bois, et al, Ann. Oncol., 2010, 21(2), pp 370-375.
[5] K.Mross, et al, Clin. Cancer Res., 2010, 16(1), pp 311-319.
[6] P.M.Ellis, et al, Clin. Cancer Res., 2010, 16(10), pp 2881-2889.
[7] I.A.Dimitroulis, et al, Respir. Care., 2014, 59(9), pp 1450-1455.
[8] N.Ahluwalia, et al, Am. J. Respir. Crit. Care Med., 2014, 190(8), pp 867-878.
[9] S.Popat, et al, Future Oncol., 2015, 11(3), pp 409-420.
[10] M.E.Mazzei, et al, Ther. Adv. Respir. Dis., 2015, 9(3), pp 121-129.
[11] R.Xu, et al, J. Labelled Comp. Radiopharm., 2015, 58(7), pp 308-312.
[12] L.Richeldi, et al, Respir. Med., 2016, 113, pp 74-79.
[13] A.Hajari Case ,et al, BMJ Open Resp. Res., 2017, 4(1), e000192.
Signal Word
Hazard Statements
Precautionary Statements
HS Code
Legal Information
Not classified as a dangerous goods

NONH for all modes of transport
Sales restrictions may apply.
1. Product Specification
2. Safety Data Sheet
Available on request.
Please inquire for pricing and availability of this product by writing email to